AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.7k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2746 trials with phase data)• Click on a phase to view related trials
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary DiseaseHyperinflation
- Interventions
- Drug: Budesonide/Glycopyrronium/Formoterol FumarateDrug: PlaceboDevice: Metered dose inhaler
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT07073950
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects With Multiple Myeloma
- Conditions
- Newly Diagnosed Multiple MyelomaRelapsed Refractory Multiple Myeloma
- Interventions
- Biological: GC012F (AZD0120)
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT07073547
- Locations
- 🇺🇸
Research site, New York, New York, United States
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT07069712
- Locations
- 🇬🇧
Research Site, Headington, United Kingdom
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT07069829
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer
- Conditions
- Breast Neoplasms
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT07070128
- Locations
- 🇧🇷
Instituto de Ciências Biológicas, Goiânia, GO, Brazil
🇧🇷Associação Hospitalar Moinhos de Vento, Porto Alegre, RS, Brazil
- Prev
- 1
- 2
- 3
- 4
- 5
- 660
- Next
News
AstraZeneca Announces $50 Billion US Investment Plan with Virginia Manufacturing Hub for Weight Management and Metabolic Drugs
AstraZeneca announces a $50 billion investment in the United States by 2030, with Virginia selected as the site for the company's largest single manufacturing facility investment globally.
Moderna Cancels mRNA Manufacturing Plant in Japan Amid Declining Vaccine Demand and Regulatory Uncertainty
Moderna has canceled plans to build an mRNA vaccine manufacturing plant at Shonan Health Innovation Park in Kanagawa Prefecture due to weak global vaccine demand and challenging business conditions.
Lisata Therapeutics Reports Promising 60% Response Rate in Pancreatic Cancer Trial with Certepetide
Lisata Therapeutics and WARPNINE completed enrollment in the Phase 1b/2a iLSTA trial evaluating certepetide in combination with standard-of-care therapy for locally advanced pancreatic ductal adenocarcinoma.
AstraZeneca Partners with CSPC for AI-Driven Drug Discovery Platform to Develop Novel Oral Therapies
AstraZeneca has entered into a strategic partnership with CSPC to leverage artificial intelligence-driven drug discovery capabilities for accelerated development of novel oral therapeutic candidates.
Sino Biopharm Acquires LaNova Medicines for $950M, Expanding Innovative Drug Pipeline
Sino Biopharm announced acquisition of remaining 95.09% stake in LaNova Medicines for up to $950 million, making it a wholly owned subsidiary.
AstraZeneca's Anselamimab Fails Primary Endpoint in Phase III AL Amyloidosis Trial, Shows Promise in Patient Subgroup
AstraZeneca's CARES Phase III clinical programme evaluating anselamimab in patients with Mayo stages IIIa and IIIb light chain amyloidosis did not achieve statistical significance for the primary endpoint of time to all-cause mortality and cardiovascular hospitalizations.
Sino Biopharmaceutical Acquires LaNova Medicines for $951 Million, Targeting PD-1xVEGF Cancer Therapies
Sino Biopharmaceutical announced plans to acquire LaNova Medicines for up to $951 million, with a net payment of approximately $500 million after accounting for cash holdings.
Ascentage Pharma Raises $192M in Oversubscribed Share Placement to Advance Cancer Pipeline
Ascentage Pharma completed a $192.3 million share placement that was oversubscribed by eight times, demonstrating strong investor confidence in the company's cancer-focused pipeline.
AstraZeneca Conducts Real-World Safety Study for Anticoagulation Reversal Agent Ondexxya
AstraZeneca is conducting an observational cohort study titled "Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation" to assess the safety and effectiveness of their anticoagulation reversal agent in real-world settings.
Eolas Therapeutics Assumes Full Development Rights to First-in-Class Orexin-1 Receptor Antagonist AZD4041 for Substance Use Disorders
Eolas Therapeutics has secured full development rights to AZD4041 from AstraZeneca, a highly selective orexin-1 receptor antagonist targeting opioid use disorder and other substance use disorders.